Immunotactoid and fibrillary glomerulonephritis characteristics
Rosenmann E, Eliakim M. Nephrotic syndrome associated with amyloid-like glomerular deposits. Nephron 1977; 18:301−308. doi: 10.1159/000180846
Alpers CE, et al.. Fibrillary glomerulonephritis: An entity with unusual immunofluorescence features. Kidney Int 1987; 31:781−789. doi: 10.1038/ki.1987.66
Schwartz MM, Lewis EJ. The quarterly case: Nephrotic syndrome in a middle-aged man. Ultrastruct Pathol 1980; 1:575−582. doi: 10.3109/01913128009140563
Korbet SM, et al.. The fibrillary glomerulopathies. Am J Kidney Dis 1994; 23:751−765. doi: 10.1016/s0272-6386(12)70290-1
Alpers CE. Fibrillary glomerulonephritis and immunotactoid glomerulopathy: Two entities, not one. Am J Kidney Dis 1993; 22:448−451. doi: 10.1016/s0272-6386(12)70151-8
Bridoux F, et al.. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 2002; 62:1764−1775. doi: 10.1046/j.1523-1755.2002.00628.x
Fogo A, et al.. Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis 1993; 22:367−377. doi: 10.1016/s0272-6386(12)70138-5
Nasr SH, et al.. Fibrillary glomerulonephritis: A report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011; 6:775−784. doi: 10.2215/CJN.08300910
Nasr SH, et al.. Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants. Kidney Int 2021; 99:410−420. doi: 10.1016/j.kint.2020.07.037
Alpers CE, Kowalewska J. Fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 2008; 19:34−37. doi: 10.1681/ASN.2007070757
Nasr SH, et al.. DNAJB9 is a specific immunohistochemical marker for fibrillary glomerulonephritis. Kidney Int Rep 2018; 3:56−64. doi: 10.1016/j.ekir.2017.07.017
Rosenstock JL, Markowitz GS. Fibrillary glomerulonephritis: An update. Kidney Int Rep 2019; 4:917−922. doi: 10.1016/j.ekir.2019.04.013
Alexander MP, et al.. Congophilic fibrillary glomerulonephritis: A case series. Am J Kidney Dis 2018; 72:325−336. doi: 10.1053/j.ajkd.2018.03.017
Said SM, et al.. Immunoglobulin-negative DNAJB9-associated fibrillary glomerulonephritis: A report of 9 cases. Am J Kidney Dis 2021; 77:454−458. doi: 10.1053/j.ajkd.2020.04.015
Said SM, et al.. DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients. Kidney Int 2020; 98:498−504. doi: 10.1016/j.kint.2020.02.025
Leung N, et al.. Monoclonal gammopathy of renal significance: When MGUS is no longer undetermined or insignificant. Blood 2012; 120:4292−4295. doi: 10.1182/blood-2012-07-445304
El Ters M, et al.. Recurrence of DNAJB9-positive fibrillary glomerulonephritis after kidney transplantation: A case series. Am J Kidney Dis 2020; 76:500−510. doi: 10.1053/j.ajkd.2020.01.018
Said SM, et al.. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney Int 2018; 94:159−169. doi: 10.1016/j.kint.2018.01.028